Meta-analysis of risk of malignancy with immunosuppressive drugs in inflammatory bowel disease

Annals of Pharmacotherapy

Volumn 41, Issue 1, 2007, Pages 21-28

  Masunaga, Yukari ^a,b   Ohno, Keiko ^a   Ogawa, Ryuichi ^a   Hashiguchi, Masayuki ^a,c   Echizen, Hirotoshi ^a   Ogata, Hiroyasu ^a  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

^b Hatsudai Rehabilitation Hospital   (Japan)

^c KITASATO UNIVERSITY   (Japan)

Author keywords

6 mercaptopurine; Azathioprine; Inflammatory bowel disease; Malignancy

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; MERCAPTOPURINE; METHOTREXATE; TACROLIMUS;

ARTICLE; CANCER; CANCER INCIDENCE; CANCER RISK; CLINICAL TRIAL; COCHRANE LIBRARY; COHORT ANALYSIS; CONTROL GROUP; CROHN DISEASE; ENTERITIS; HUMAN; MEDLINE; META ANALYSIS; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; ULCERATIVE COLITIS;

COHORT STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; NEOPLASMS; RISK FACTORS;

EID: 33846448180     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H219     Document Type: Article

References (41)

1. Korelitz BI, Glass JL, Wisch N. Long-term immunosuppressive therapy of ulcerative colitis. Continuation of a personal series. Am J Dig Dis 1973;18:317-22.
2. Haber CJ, Meltzer SJ, Present DH, Korelitz BI. Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease. Gastroenterology 1986;91:982-6.
3. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989;111:641-9.
4. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005;54:1121-5.
5. Sheil AG, Disney AP, Mathew TH, Livingston BE, Keogh AM. Lymphoma incidence, cyclosporine, and the evolution and major impact of malignancy following organ transplantation. Transplant Proc 1997;29:825-7.
6. Kishikawa H, Ichikawa Y, Yazawa K, et al. Malignant neoplasm in kidney transplantation. Int J Urol 1998;5:521-5.
7. Gaya SB, Rees AJ, Lechler RI, Williams G, Mason PD. Malignant disease in patients with long-term renal transplants. Transplantation 1995;59:1705-9.
8. Jones M, Symmons D, Finn J, Wolfe F. Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study. Br J Rheumatol 1996;35:738-45.
9. Asten P, Barrett J, Symmons D. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases. J Rheumatol 1999;26:1705-14.
10. Kinlen LJ. Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Am J Med 1985;78:44-9.
11. Kinlen LJ, Sheil AG, Peto J, Doll R. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J 1979;2:1461-6.
12. Kinlen LJ. Malignancy in autoimmune diseases. J Autoimmun 1992;5(suppl A):363-71.
13. Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 1990;323:1228-33.
14. Gillen CD, Andrews HA, Prior P, Allan RN. Crohn's disease and colorectal cancer. Gut 1994;35:651-5.
15. Choi PM, Zelig MP. Similarity of colorectal cancer in Crohn's disease and ulcerative colitis: implications for carcinogenesis and prevention. Gut 1994;35:950-4.
16. Langholz E, Munkholm P, Davidsen M, Binder V. Colorectal cancer risk and mortality in patients with ulcerative colitis. Gastroenterology 1992;103:1444-51.
17. Gyde S. Screening for colorectal cancer in ulcerative colitis: dubious benefits and high costs. Gut 1990;31:1089-92.
18. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Commun Health 1998;52:377-84.
19. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001;91:854-62.
20. Metge CJ, Blanchard JF, Peterson S, Bernstein CN. Use of pharmaceuticals by inflammatory bowel disease patients: a population-based study. Am J Gastroenterol 2001;96:3348-55.
21. Petti DB. Statistical methods in meta-analysis. In: Petitti DB. Meta-analysis, decision analysis, and cost-effectiveness analysis: methods for quantitative synthesis in medicine. 2nd ed. New York: Oxford Press, 2000:107-16.
22. Morizane T. [EBM upgrade for physicians] Japanese. Tokyo: Igakushoin, 2002:133-7, 149-63.
23. Matula S, Croog V, Itzkowitz S, et al. Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine. Clin Gastroenterol Hepatol 2005;3:1015-21.
24. Fraser AG, Orchard TR, Robinson EM, Jewell DP. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 2002;16:1225-32.
25. Lewis JD, Bilker WB, Brensinger C, Deren JJ, Vaughn DJ, Strom BL. Inflammatory bowel disease is not associated with an increased risk of lymphoma. Gastroenterology 2001;121:1080-7.
26. Farrell RJ, Ang Y, Kinlen P, et al. Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut 2000;47:514-9.
27. Korelitz BI, Mirsky FJ, Fleisher MR, Warman JI, Wisch N, Gleim GW. Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine. Am J Gastroenterol 1999;94:3248-53.
28. Bouhnik Y, Lémann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996;347:215-9.
29. George J, Present DH, Pou R, Bodian C, Rubin PH. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996;91:1711-4.
30. Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994;343:1249-52.
31. Lobo AJ, Foster PN, Burke DA, Johnston D, Axon AT. The role of azathioprine in the management of ulcerative colitis. Dis Colon Rectum 1990;33:374-7.
32. Sandborn WJ, Sutherland LR, Pearson DC, May GR, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000;(2):CD000545.
33. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000;(2):CD000067.
34. Hanauer SB, Sandborn W. Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn's disease in adults. Am J Gastroenterol 2001;96:635-43.
35. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001;48:526-35.
36. Ekbom A, Helmick C, Zack M, Adami HO. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet 1990;336:357-9.
37. Fireman Z, Grossman A, Lilos P, et al. Intestinal cancer in patients with Crohn's disease. A population study in central Israel. Scand J Gastroenterol 1989;24:346-50.
38. Jess T, Loftus EV Jr, Velayos FS, et al. Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted County, Minnesota. Gastroenterology 2006;130:1039-46.
39. Freidman S, Blumberg RS. Inflammatory bowel disease. In: Braunwald E, Fauci AS, Kasper DL, Hauser SL, Longo DL, Jameson JL, eds. Harrison's principles of internal medicine. 15th ed. New York: McGraw-Hill, 2001:1679.
40. Collins PD, Mpofu C, Watson AJ, Rhodes JM. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2006;(2):CD000279.
41. Rutter MD, Saunders BP, Wilkinson KH, et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006;130:1030-8.